Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

Published on 24 May 2024 on Zacks via Yahoo Finance

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

Verastem Oncology VSTM announced positive interim safety and efficacy data from the dose level 1 cohort of its early to mid-stage study evaluating avutometinib and defactinib in combination with standard-of-care first-line chemotherapy (gemcitabine and Nab-paclitaxel) in metastatic pancreatic cancer patients.

Both avutometinib and defactinib have been in-licensed by Verastem from other pharmaceutical companies. Avutometinib is an RAF/MEK clamp, while defactinib is a best-in-class selective FAK inhibitor.

Read the rest of the article

NASDAQ.VSTM price evolution

NYSE.ANVS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

News

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

NASDAQ.VSTM price evolution

NYSE.ANVS price evolution

Want to become a better investor?

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.01% By Investing.com

Crude Oil Rises 1%; Verastem Shares Slide - Verastem (NASDAQ:VSTM)

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

Ovarian cancer drug developer's stock cut in half after it files for FDA approval - Boston Business...

What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?

Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc

Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)

Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy

Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year loss

10 Top Penny Stocks for 2023